The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease

Valerio Nobili, Giorgio Bedogni, Benedetta Donati, Anna Alisi, Luca Valenti

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) -59% to -42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD.

Original languageEnglish
Pages (from-to)957-960
Number of pages4
JournalJournal of Medicinal Food
Volume16
Issue number10
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Docosahexaenoic Acids
Phospholipases
Confidence Intervals
Alleles
Genotype
Placebos
Protein Domains
Non-alcoholic Fatty Liver Disease
Randomized Controlled Trials

Keywords

  • children
  • docosahexaenoic acid
  • non-Alcoholic fatty liver disease
  • randomized controlled trial

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease. / Nobili, Valerio; Bedogni, Giorgio; Donati, Benedetta; Alisi, Anna; Valenti, Luca.

In: Journal of Medicinal Food, Vol. 16, No. 10, 01.10.2013, p. 957-960.

Research output: Contribution to journalArticle

@article{2313dfbf21c94a0895be721e916c5104,
title = "The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease",
abstract = "The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50{\%} lower [95{\%} confidence interval (CI) -59{\%} to -42{\%})] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37{\%}, 95{\%} CI 26-48{\%}) for the PNPLA3 M/M versus I/M genotype and lower (-12{\%}, 95{\%} CI -21{\%} to -3{\%}) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD.",
keywords = "children, docosahexaenoic acid, non-Alcoholic fatty liver disease, randomized controlled trial",
author = "Valerio Nobili and Giorgio Bedogni and Benedetta Donati and Anna Alisi and Luca Valenti",
year = "2013",
month = "10",
day = "1",
doi = "10.1089/jmf.2013.0043",
language = "English",
volume = "16",
pages = "957--960",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease

AU - Nobili, Valerio

AU - Bedogni, Giorgio

AU - Donati, Benedetta

AU - Alisi, Anna

AU - Valenti, Luca

PY - 2013/10/1

Y1 - 2013/10/1

N2 - The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) -59% to -42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD.

AB - The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-Alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) -59% to -42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26-48%) for the PNPLA3 M/M versus I/M genotype and lower (-12%, 95% CI -21% to -3%) for the I/I versus I/M genotype (Somers' D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD.

KW - children

KW - docosahexaenoic acid

KW - non-Alcoholic fatty liver disease

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84885970553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885970553&partnerID=8YFLogxK

U2 - 10.1089/jmf.2013.0043

DO - 10.1089/jmf.2013.0043

M3 - Article

C2 - 24074360

AN - SCOPUS:84885970553

VL - 16

SP - 957

EP - 960

JO - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 10

ER -